Hydroxyurea is an antineoplastic agent, prescribed for sickle cell anemia, several types of cancer (such as melanoma, chronic myelogenous leukemia, squamous cell carcinomas), as an adjunct to ...
Background: The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback